Rezolute Inc. (RZLT) reported Q2 2025 results with no revenue and a continued operating loss, reflecting the company’s pre-revenue, clinical-stage business model. For the quarter, operating expenses totaled $17.08 million driven primarily by R&D spending of $12.63 million and G&A of $4.45 million, yielding an operating loss of $17.08 million and a net loss of $15.73 million (EPS -0.22). The company ended the period with a robust liquidity buffer, including $8.93 million in cash and $87.61 million in short-term investments, for a total of about $96.5 million in cash and investments, supporting ongoing RZ358 and RZ402 development programs. The quarter showed negative net income QoQ (-2.29%) and negative operating income (-0.82%), while YoY comparisons reflect some improvement in absolute loss metrics (operating income YoY -12.41%, net income YoY -13.09%, and EPS YoY +18.5%), underscoring progress in cost control and the company’s ability to sustain pipeline activities without a near-term revenue base.
Key implications for investors: (1) the balance sheet remains materially liquidity-driven with minimal near-term debt, (2) the business remains heavily R&D-funded with no guaranteed revenue until outcomes from pivotal trials, and (3) the near-term value hinges on clinical readouts and potential partnership activity around RZ358 (congenital hyperinsulinism) and RZ402 (diabetic macular edema). The substantial cash runway enhances optionality but also highlights the high-risk, high-reward profile typical of early-stage biopharmaceuticals. A constructive read-through for investors is centered on milestone-driven milestones and potential strategic collaborations that could unlock value before a path to commercial revenue materializes.
Key Performance Indicators
Operating Income
Decreasing
-17.08M
QoQ: -0.82% | YoY: -12.41%
Net Income
Decreasing
-15.73M
QoQ: -2.29% | YoY: -13.09%
EPS
Increasing
-0.22
QoQ: 0.00% | YoY: 18.52%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue: No reported revenue in QQ2 2025 (N/A YoY/QoQ); Gross Profit: N/A; Gross Profit Margin: N/A.
Expenses and profitability:
- Research and Development Expenses: $12.627 million
- General and Administrative Expenses: $4.453 million
- Selling and General Administrative (SG&A): $4.453 million
- Operating Expenses (costs and expenses): $17.080 million
- Depreciation and Amortization: $0.008 million
- EBITDA: $(15.722) million
- Operating Income: $(17.080) million
- Total Other Income (Expense), Net: $1.350 million
- Income Before Tax: $(15.730) million
- Net Income: $(15.730) million
- Earnings Per Share (EPS): $(0.22) (diluted: $(0.22))
- Weighted Average Shares Outstanding: 69.94 million
Liquidity and cash flows:
- Net Cash Provided By Operating Activities: $(13.666) million
- Depreciation/Amortization: $0.008 million
- Stock-Based Compensation: $1.445 million
- Change in Working Capital: $(1.208) million
- Accounts Payables: $0.991 million
- Other Working Capital: $0.217 million
- Net Change in Cash: $(1.54) million
- Cash at End of Period: $8.932 million
- Cash at Beginning of Period: $10.472 million
- Free Cash Flow: $(13.666) million
Balance sheet and leverage:
- Total Current Assets: $98.694 million
- Total Assets: $112.007 million
- Total Current Liabilities: $10.608 million
- Total Liabilities: $12.418 million
- Total Stockholders’ Equity: $99.589 million
- Retained Earnings: $(360.552) million
- Net Cash (Debt) Position: Net cash positive; Net Debt: $(7.0) million (per provided ratios)
- Cash and Short-Term Investments: $96.54 million (cash + short-term investments)
- Debt: Long-term debt $1.333 million; Short-term debt $1.198 million
- Current ratio: 9.30x; Quick ratio: 9.30x
- Price-to-Book: 3.44x; Enterprise Value: Negative, driven by cash holdings
YoY vs QoQ context:
- Operating Income YoY: -12.41%; QoQ: -0.82%
- Net Income YoY: -13.09%; QoQ: -2.29%
- EPS YoY: +18.52%; QoQ: 0.00%
Notes: Revenue remained nil in QQ2 2025, consistent with Rezolute’s clinical-stage model. The company’s quarterly results continue to reflect heavy R&D investment ahead of potential clinical milestones.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-17.08M
-12.41%
-0.82%
Net Income
-15.73M
-13.09%
-2.29%
EPS
-0.22
18.52%
0.00%
Key Financial Ratios
Return on Assets
Weak
-0.14%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.16%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
9.30
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.02
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-5.45x
Negative earnings make P/E ratio not meaningful
Price to Book
Premium
3.44x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.